Approvals/TGA/ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion

Approved

STANDARD

ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion

Servier Laboratories (Aust) Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: bb15cffaa03324e7
Product Name: ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion
Artg Id: 263184
Artg Name: ONIVYDE irinotecan (as sucrosofate) 43 mg/10 mL nanoliposomal concentrated injection for infusion
Sponsor: Servier Laboratories (Aust) Pty Ltd
Company Detail Path: /organization/servier-laboratories-aust-pty-ltd
Artg Date: 2016-12-19
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/b2c4b11a6070db4582331e3a55819199.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/0e2e3b907e4aed28032a3dffa5455654.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 29, 2025

Approval ID

bb15cffaa03324e7

Type

Standard